Ophthalmic

Corza Medical & Envision announce strategic partnership

Retrieved on: 
Thursday, September 28, 2023
Envision, Partnership, Employment, Education, Quality of life, Paratriathlon, Rehabilitation, Research, Ophthalmic, Social justice, Patient, Empathy, Nursing

WESTWOOD, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) and Envision are pleased to announce today that they have entered into a strategic partnership, combining Corza’s industry-leading innovative surgical technologies, training, and medical education with Envision’s commitment and dedication to programs that center around employment, outreach, rehabilitation, education, and research providing inspiration and opportunity for people who are blind or visually impaired.

Key Points: 
  • WESTWOOD, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) and Envision are pleased to announce today that they have entered into a strategic partnership, combining Corza’s industry-leading innovative surgical technologies, training, and medical education with Envision’s commitment and dedication to programs that center around employment, outreach, rehabilitation, education, and research providing inspiration and opportunity for people who are blind or visually impaired.
  • “In today's modern business landscape, technological advancements play a crucial role in ensuring success,” said Tom Testa Corza Medical CEO.
  • Curious: maintain a sense of wonder, are brave in our questioning, keep an open perspective, and engage with the wider world.
  • “Envision’s industry-leading products, training, education, and research dovetail perfectly with Corza Medical,” said Michael Monteferrante, Envision President and CEO.

Implantable Medical Devices Market to grow by USD 51.1 billion from 2022-2027 | North America to account for 45% of market growth - Technavio

Retrieved on: 
Tuesday, September 26, 2023
LivaNova, Prevalence, Osteoporosis, Abbott Laboratories, Tetraplegia, Segment, National Center for Spinal Disorders, SE, Stryker Corporation, Rheumatoid arthritis, Dental implant, Gout, Hip, Zimmer Biomet, Lupus, Cardinal Health, USD, CDC, Medial knee injuries, Boston Scientific, Circulatory system, Growth, Assurant, Orthopedic surgery, Trauma, Clifton Springs Hospital & Clinic, Arthritis, Hospital, NuVasive, Research, Arthropathy, Knee, Laboratory, AbbVie, Ophthalmic, ROW, Korea Disease Control and Prevention Agency, Fibromyalgia, Medtronic, Medical device, Retail, Application, Geography

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.
  • Hence, such factors drive the growth of the implantable medical devices market during the forecast period.
  • Detailed information on factors that will drive the growth of the implantable medical devices market between 2022 and 2027.
  • Growth of the implantable medical devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of implantable medical devices market vendors.

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Retrieved on: 
Thursday, July 27, 2023
CELU, Ophthalmic, Allotransplantation, Instituto de Biologia Molecular e Celular, Ringless voicemail, Physician, Patient, Extracellular matrix, Wound healing, Telescopic sight

BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.

Key Points: 
  • BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.
  • BIOVANCE® 3L Ocular is acellular and consists of three layers of an amniotic membrane that supports treatment of advanced ocular surface disease.
  • As a barrier membrane, BIOVANCE® 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries.
  • “We are excited to partner with Verséa Ophthalmics to distribute our BIOVANCE® and BIOVANCE® 3L Ocular products in the U.S.,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder.

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

Retrieved on: 
Tuesday, July 25, 2023
Health, Surgery, Other Science, General Health, Research, Science, Optical, DED, Ophthalmic, OTCQB, OSD, Biomarker, Lactoferrin, Telecanthus, MD, Patient, Allergic conjunctivitis, Diagnosis, Tear, Immunoglobulin E, Pharmaceutical industry, Medical imaging

T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management of patients suffering from ocular surface disease (OSD).

Key Points: 
  • T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management of patients suffering from ocular surface disease (OSD).
  • While today marks a milestone for the company with this initial shipment of its novel testing platform, it represents only the first phase that will focus on TOTAL IgE.
  • Rob Sambursky, MD, President of Verséa Ophthalmics stated: “Verséa Ophthalmics is proud to bring the innovative T-POC Quantitative Testing Platform to eye care professionals to aid them in appropriately diagnosing, managing, and treating their patients with ocular surface disease.
  • For more information on the T-POC Quantitative Testing Platform, please visit www.versea.com/ophthalmics .

Ocular Therapeutix™ Announces Appointment of New Board Member

Retrieved on: 
Wednesday, July 12, 2023
Opus, University, Refractive surgery, Doctor of Philosophy, Emeritus, Stanford University, Eye, Himalayan Cataract Project, Research, ASCRS, RD, Ophthalmic, The Many Ghosts of Doctor Graves, Grave, Ophthalmology, OWL, Alcon, Brown University, ISCB Senior Scientist Award, Akorn, FFB, Cataract, Therapy, Society, Pharmaceutical industry, Management, Psychology

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.

Key Points: 
  • BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.
  • A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves brings extensive experience to her role.
  • Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory.
  • She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.

BNS Ophthalmics appoints Joseph Papa and Ari Kellen to the Board of Directors

Retrieved on: 
Wednesday, June 21, 2023
University, Bausch Health, Hebrew University of Jerusalem, IPO, University of Connecticut School of Business, BNS, Kellogg School of Management, Ari, Risk management, MBA, McKinsey & Company, Bausch & Lomb, Science, Patient, School, Partnership, Pharmacy school, Knowledge, Growth, DSM-IV codes, BNSO, Medical degree, Northwestern University Master of Product Design and Development Management, Management, Pharmaceutical industry, Pharmacy, Ophthalmic, Bausch, University of the Witwatersrand, Ophthalmology

ATHENS, Greece, June 21, 2023 /PRNewswire/ -- BNS Ophthalmics (BNSO) is pleased to announce the appointments of Joseph Papa and Ari Kellen to the Board of Directors.

Key Points: 
  • ATHENS, Greece, June 21, 2023 /PRNewswire/ -- BNS Ophthalmics (BNSO) is pleased to announce the appointments of Joseph Papa and Ari Kellen to the Board of Directors.
  • Joseph and Ari, having worked together, bring an impressive and successful track record of leadership and achievements.
  • The presence of Joseph and Ari in the BNSO Board reflects their confidence in BNSO scientific potential and excitement about the future prospects of BNSO.
  • Aris Mitsopoulos, Vice President of RAFARM and CEO of BNSO, stated: "We are thrilled to welcome Joseph Papa and Ari Kellen, to our esteemed Board of Directors.

MediPrint® Ophthalmics Announces Promising Results from Its SIGHT-2 Phase 2b Group 1 Clinical Study

Retrieved on: 
Friday, June 9, 2023
Science, Research, Pharmaceutical, Optical, General Health, Health, Medical Devices, Clinical Trials, Contact, Glaucoma, IOP, Interim, Ocular hypertension, Life, Intraocular pressure, Group 1, Ophthalmic, Eye, Clinical trial, Timolol, Lens, LL, Trial of the century, Patient, FDA, Safety, CBCC, Pharmaceutical industry, Telescopic sight

Today, MediPrint® Ophthalmics (MediPrint), an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has completed its SIGHT-2 dose-finding Phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma.

Key Points: 
  • Today, MediPrint® Ophthalmics (MediPrint), an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has completed its SIGHT-2 dose-finding Phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma.
  • The SIGHT-2 Phase 2b Group 1 results trajectory is positive and promising.
  • The SIGHT-2 Phase 2b Group 2 study is planned with the LL-BMT1 (medium dose) lens.
  • “I am enthusiastic about the SIGHT-2 Phase 2b Group 1 clinical study results because they indicate that the path to get to our Phase 3 study and to an FDA approval is clear and achievable,” commented Praful Doshi, Founder, Chairman, and Interim CEO.

Framing the issues at a May 18th event about proposed Eyeglass Rule changes

Retrieved on: 
Sunday, June 4, 2023
Insurance, Federal Trade Commission Act of 1914, Industry, Rule, Notice of proposed rulemaking, Federal Trade Commission, Policy, Ophthalmology, Record, Prescription, Glasses, Blog, Ophthalmic, Privacy, Thought, Constitution Center (Washington, D.C.), Federal Register, Patient, Social Security, FTC, Comment, Compliance, Social, Fraud, Cryptocurrency, Pharmaceutical industry

Framing the issues at a May 18th event about proposed Eyeglass Rule changes

Key Points: 

Framing the issues at a May 18th event about proposed Eyeglass Rule changes

BNS and RAFARM create BNS Ophthalmics to leverage nanotechnology in the development of novel ophthalmic products

Retrieved on: 
Tuesday, May 30, 2023
Transfer, Hebrew University of Jerusalem, Cornea, Partnership, BNS, Macular edema, Tacrolimus, IP, Telecanthus, Patient, Water, FDA, BNSO, Nanotechnology, Safety, Pharmaceutical industry, Ophthalmic, Ophthalmology

BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world.

Key Points: 
  • BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world.
  • BNS will contribute its intellectual property and R&D expertise to BNSO while Rafarm will provide appropriate funding, together with infrastructure for development, commercial scale manufacturing, and distribution.
  • Our collaboration with BNS, whom we recognize as a leader in the field of nanotechnology, marks a significant milestone of RAFARM in innovative technologies.
  • We join forces with BNS for the development and production of novel therapeutic products and to further expand our expertise in ophthalmics."

FTC Releases Agenda for May 18 Workshop on Proposed Changes to the Eyeglass Rule

Retrieved on: 
Thursday, May 4, 2023
Contact, Consumer protection, Insurance, Method, Glasses, Contact lens, DC, Prescription, Blog, Ophthalmic, Federal Trade Commission, Patient, FTC, Webcast, News, Social media, Financial adviser, Health insurance, Dietary supplement

The Federal Trade Commission released the tentative agenda for its May 18 workshop in Washington, DC, which will examine proposed changes to its Ophthalmic Practice Rules, also known as the Eyeglass Rule.

Key Points: 
  • The Federal Trade Commission released the tentative agenda for its May 18 workshop in Washington, DC, which will examine proposed changes to its Ophthalmic Practice Rules, also known as the Eyeglass Rule.
  • The workshop, A Clear Look at the Eyeglass Rule, is free and open to the public, and pre-registration is not required.
  • This panel will consider the need for the Eyeglass Rule’s prescription release requirement in today’s marketplace.
  • Follow the FTC on social media, read consumer alerts and the business blog, and sign up to get the latest FTC news and alerts.